As of 11:30 AM on the 29th, Antrogen's stock price remains unchanged from the previous day at 63,400 KRW, with a trading volume of 261,471 shares, which is 17.89% of the 5-day average trading volume. On May 21, Antrogen became a market issue with the headline "Antrogen surges for the second day following FDA approval of diabetic foot ulcer treatment."
In addition to Antrogen, posts from investors are also rapidly increasing for Daewoong Pharmaceutical (069620), Blossom M&C (263920), and A-Root (096690).

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

